Betamethasone

Betamethasone is a potent topical corticosteroid used to treat inflammatory skin conditions including eczema, psoriasis, and dermatitis.

It works by suppressing the immune-mediated inflammatory response in the skin, reducing redness, itching, swelling, and scaling.

Betamethasone is available in multiple formulations including cream, ointment, lotion, and scalp application, and is classified as a prescription-only medicine (POM) in the UK.

Want to buy Betamethasone without a prescription?

You can order Betamethasone here. Fill in a short form. A UK doctor checks if it is right for you.

If yes, it ships fast in a plain box.

How to order Betamethasone

  1. Find the drug you need on our site.
  2. Pick a clinic. See the price.
  3. Fill in a short health form.
  4. A doctor reads your form.
  5. If it is safe for you, they say yes.
  6. Your order ships fast to your door.
  7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Betamethasone on Prescriptsy

Betamethasone is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Betamethasone is a potent topical corticosteroid widely prescribed in the United Kingdom for the management of moderate to severe inflammatory skin conditions, including atopic eczema (atopic dermatitis), psoriasis, contact dermatitis, and other steroid-responsive dermatoses.

It is one of the most commonly used potent corticosteroids in UK primary and secondary care, available as betamethasone valerate 0.1% and betamethasone dipropionate 0.05% in formulations including cream, ointment, lotion, and scalp application.

Topical corticosteroids remain the mainstay of pharmacological treatment for inflammatory skin disease, and betamethasone occupies a central position in the potency ladder.

This page provides a comprehensive clinical overview of betamethasone, covering its mechanism of action, approved indications, correct application technique, treatment duration, side effects, safety warnings, and how to obtain a prescription in the UK.

All information follows current guidance from the British National Formulary (BNF), NICE, and the MHRA.

Important safety information about betamethasone

Before using betamethasone, note the following critical safety points. Betamethasone at potent strengths is a prescription-only medicine (POM) in the UK.

  • Do not apply betamethasone to infected skin (bacterial, fungal, or viral) unless an appropriate antimicrobial is being used concurrently. Corticosteroids suppress the local immune response and can allow infections to worsen.
  • Do not use on the face for more than 5 days unless specifically directed by a dermatologist.
  • Keep treatment courses as short as possible. Prolonged or widespread use of potent corticosteroids increases the risk of skin thinning, stretch marks, and systemic absorption.
  • In children, use only under specialist supervision and for the shortest effective duration.

What are topical corticosteroids

Topical corticosteroids are anti-inflammatory medicines applied directly to the skin.

They are classified by potency in the BNF into four categories: mild (such as hydrocortisone 0.5 to 1%), moderate (such as clobetasone butyrate 0.05%), potent (such as betamethasone valerate 0.1%), and very potent (such as clobetasol propionate 0.05%).

The choice of potency depends on the severity of the condition, the body site, the patient's age, and the duration of treatment required.

Potent corticosteroids like betamethasone are reserved for moderate to severe inflammatory dermatoses that have not responded adequately to mild or moderate preparations.

They are particularly effective for thicker, more resistant plaques of psoriasis and for severe eczema flares on the trunk and limbs.

Thinner skin areas, including the face, axillae, and groin, generally require milder preparations to avoid local side effects.

How betamethasone works

Betamethasone is a synthetic fluorinated glucocorticoid. When applied to the skin, it penetrates the stratum corneum and binds to intracellular glucocorticoid receptors in keratinocytes, fibroblasts, and immune cells.

The activated receptor-ligand complex translocates to the cell nucleus and modulates gene transcription, suppressing the production of pro-inflammatory mediators including interleukins (IL-1, IL-6), tumour necrosis factor-alpha (TNF-alpha), prostaglandins, and leukotrienes.

The resulting clinical effects include reduction of erythema (redness) through vasoconstriction, decreased oedema through reduced capillary permeability, suppression of itching through inhibition of inflammatory mediators, and reduced scaling and lichenification as the inflammatory stimulus is removed.

Betamethasone also inhibits the migration and activation of leucocytes at the site of inflammation, further dampening the immune response that drives conditions such as eczema and psoriasis.

Betamethasone valerate and betamethasone dipropionate are both classified as potent, though betamethasone dipropionate has slightly higher lipophilicity, allowing greater skin penetration. The choice between the two depends on clinical context and the prescriber's assessment.

Conditions treated with betamethasone

Atopic eczema (atopic dermatitis)

Atopic eczema is a chronic, relapsing inflammatory skin condition affecting approximately 15 to 20% of children and 2 to 10% of adults in the UK.

It causes intense itching, dry skin, erythema, and in severe cases, exudation, crusting, and lichenification.

NICE Clinical Guideline CG57 recommends a stepped approach to treatment, with emollients as the foundation and topical corticosteroids of appropriate potency used for flares.

Betamethasone is typically used as a short-course treatment for moderate to severe flares on the trunk and limbs, with step-down to a milder corticosteroid once the flare is controlled.

Psoriasis

Psoriasis is an immune-mediated, chronic inflammatory skin condition characterised by well-defined, erythematous plaques with silvery-white scale. It affects approximately 1.5 to 2% of the UK population.

Topical corticosteroids are a first-line treatment for mild to moderate plaque psoriasis, often in combination with a vitamin D analogue (such as calcipotriol).

Betamethasone is available in fixed-combination preparations with calcipotriol for the treatment of scalp and body psoriasis.

NICE Technology Appraisal guidance supports the use of potent corticosteroids as short-term treatment for psoriasis flares, followed by vitamin D analogues for maintenance.

Contact dermatitis

Contact dermatitis is an inflammatory reaction triggered by direct skin contact with an irritant substance (irritant contact dermatitis) or an allergen (allergic contact dermatitis).

It presents with erythema, vesicles, and pruritus in the affected area.

Identification and avoidance of the causative agent is the primary intervention, but topical corticosteroids are used to reduce acute inflammation during flares.

Other steroid-responsive dermatoses

Betamethasone may also be prescribed for seborrhoeic dermatitis, discoid lupus erythematosus, lichen planus, and insect bite reactions that are not responding to milder treatments. In all cases, the prescriber will select the lowest effective potency for the shortest necessary duration.

Application technique and dosing

Correct application technique maximises therapeutic benefit and minimises the risk of side effects. Wash and dry the affected area before application.

Squeeze a thin ribbon of cream or ointment along the length of your fingertip (from the tip to the first crease).

This is one fingertip unit (FTU), approximately 0.5 g, and covers an area equivalent to two adult palms laid flat.

Apply the preparation to the affected skin in a thin, even layer and rub in gently in the direction of hair growth.

Avoid vigorous rubbing, which can increase skin irritation. Wash your hands immediately after application unless the hands are the treatment area.

Do not apply betamethasone to broken skin, ulcerated areas, or mucous membranes unless specifically directed.

The standard regimen is once or twice daily application.

NICE and the BNF recommend that once-daily application is sufficient for most patients and is associated with fewer local side effects than twice-daily use.

Treatment courses should typically last 7 to 14 days, with a maximum of 4 weeks on any single area before clinical review.

Once the flare is controlled, step down to a milder corticosteroid or switch to emollient-only maintenance.

Emollients and corticosteroid timing

Emollients (moisturisers) should be used liberally and frequently alongside topical corticosteroids. They restore the skin barrier, reduce water loss, and improve the penetration and efficacy of the corticosteroid.

If both are applied at the same time, apply the emollient first and wait 20 to 30 minutes before applying betamethasone, or use them at different times of the day.

Applying a corticosteroid immediately after an emollient can dilute the corticosteroid and spread it beyond the target area.

Clinical evidence and guidelines

NICE Clinical Guideline CG57 (Atopic eczema in under 12s) and NICE Quality Standard QS44 recommend the use of potent topical corticosteroids for moderate to severe eczema flares, with the principle of using the least potent preparation that controls the disease.

The Primary Care Dermatology Society (PCDS) and British Association of Dermatologists (BAD) provide similar stepwise guidance for adults.

For psoriasis, NICE Clinical Guideline CG153 recommends a potent topical corticosteroid as first-line treatment for trunk and limb psoriasis, applied once or twice daily for up to 4 weeks, ideally in combination with a vitamin D analogue.

Fixed-combination betamethasone/calcipotriol preparations have been evaluated in multiple randomised controlled trials and are endorsed for both initial treatment and as-needed maintenance in scalp and body psoriasis.

Systematic reviews have confirmed that potent topical corticosteroids, including betamethasone valerate, are significantly more effective than placebo in reducing eczema severity scores (SCORAD, EASI) and psoriasis area severity (PASI) at 2 to 4 weeks.

Ointment formulations are generally more effective than creams for dry, lichenified skin, though patient preference and the body site influence formulation choice.

Side effects of betamethasone

Local side effects

The most common adverse effects are local and related to the duration and site of application.

Mild burning, stinging, or itching at the application site may occur initially and usually resolves quickly.

Prolonged or inappropriate use can cause irreversible skin changes including epidermal and dermal atrophy (thinning), striae (stretch marks), telangiectasia (visible dilated blood vessels), purpura, and hypopigmentation.

Perioral dermatitis, steroid rosacea, and acneiform eruptions can develop with prolonged facial application.

Systemic side effects

Systemic absorption is generally minimal with correct short-term use on limited body areas.

However, risk increases significantly with potent preparations used over large surface areas, under occlusive dressings, on damaged skin, or for prolonged periods.

Potential systemic effects include hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushingoid features, hyperglycaemia, and in children, growth retardation.

Periocular application carries the risk of raised intraocular pressure and posterior subcapsular cataract.

Rebound flare

Abrupt discontinuation after prolonged use may trigger a rebound exacerbation of the underlying condition. Gradual reduction in application frequency (for example, from daily to alternate days, then twice weekly) helps prevent this phenomenon and is recommended when stepping down treatment.

When to seek medical advice

Contact your GP or NHS 111 if you develop new or worsening redness, pustules, pain, or signs of skin infection during treatment.

Seek medical advice if you notice skin thinning, stretch marks, or if your condition is not improving after 2 weeks of treatment.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Infection risk

Corticosteroids suppress the local immune response and can mask or worsen skin infections.

Do not apply betamethasone to skin affected by untreated bacterial, fungal, or viral infection (including impetigo, athlete's foot, herpes simplex, chickenpox, or shingles).

If secondary infection develops during treatment, an appropriate antimicrobial should be started and the corticosteroid may need to be paused until the infection is controlled.

Face and flexural areas

Potent corticosteroids should not be applied to the face, eyelids, or flexures (armpits, groin, under breasts) for more than 5 days without dermatologist supervision. These areas have thinner skin with greater corticosteroid absorption, increasing the risk of atrophy and telangiectasia.

Children

Children are at greater risk of systemic absorption because of their higher body-surface-area-to-weight ratio and thinner skin.

Potent topical corticosteroids should only be used in children under specialist supervision.

Nappy areas in infants create a natural occlusive environment and should not be treated with potent corticosteroids.

Pregnancy and breastfeeding

There is limited evidence on the safety of topical betamethasone in pregnancy, but extensive or prolonged use should be avoided.

Small amounts applied to limited areas for short durations are considered low risk. During breastfeeding, betamethasone should not be applied to the breast before feeding.

Discuss the benefit-risk balance with your prescriber.

How to get a betamethasone prescription in the UK

Betamethasone at potent concentrations is a prescription-only medicine (POM) in the UK. It cannot be purchased over the counter.

To obtain a prescription, consult your GP, who will assess the type and severity of your skin condition, review your treatment history, and determine whether a potent corticosteroid is appropriate.

Referral to a consultant dermatologist may be warranted for severe, widespread, or treatment-resistant disease.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) may also prescribe betamethasone following a structured consultation with supporting photographs or clinical history.

All UK prescriptions are dispensed by registered pharmacies.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with eczema and psoriasis: practical tips

Topical corticosteroids manage flares, but long-term skin health depends on consistent daily care.

Apply emollients generously and frequently, even when the skin appears clear, to maintain the skin barrier.

Use soap substitutes (emollient wash products) instead of standard soap, shower gel, or bubble bath, which strip natural skin oils.

Wear loose-fitting cotton clothing to reduce friction and irritation. Keep fingernails short to minimise damage from scratching.

Identify and avoid known triggers, which may include certain fabrics, fragrances, extremes of temperature, stress, and specific foods in some individuals.

For psoriasis, controlled sunlight exposure (without burning) can improve symptoms.

Psychological support is available through the NHS and patient organisations such as the National Eczema Society and the Psoriasis Association for those struggling with the emotional impact of visible skin disease.

When to seek urgent medical advice

Contact your GP or NHS 111 if your skin condition worsens significantly, if you develop widespread redness and scaling (which may indicate erythroderma), or if you notice signs of skin infection such as increasing pain, pus, or spreading redness.

Eczema herpeticum (herpes simplex infection of eczematous skin) presents with clusters of painful blisters and is a dermatological emergency requiring urgent antiviral treatment.

Call 999 or attend A&E if you experience signs of anaphylaxis or a severe systemic allergic reaction.

Sources

Medical information

Betamethasone belongs to the potent (Group III) category of topical corticosteroids as classified in the BNF. The active forms used in topical preparations are betamethasone valerate (0.1%) and betamethasone dipropionate (0.05%), both of which exert anti-inflammatory, antipruritic, and vasoconstrictive effects. Betamethasone binds to intracellular glucocorticoid receptors and modulates gene transcription, suppressing the production of pro-inflammatory cytokines, prostaglandins, and leukotrienes. This reduces capillary permeability, leucocyte migration, and the inflammatory cascade responsible for the clinical features of eczema and psoriasis. Topical betamethasone is indicated for short-term management of inflammatory dermatoses responsive to corticosteroids. It should not be used on the face or flexures for prolonged periods without specialist supervision.

Dosage guidance

Apply a thin layer of betamethasone cream or ointment to the affected area(s) once or twice daily, as directed by your prescriber. Use the fingertip unit (FTU) method to gauge the appropriate quantity: one FTU (approximately 0.5 g, squeezed from a standard nozzle along an adult fingertip) is sufficient to cover an area roughly the size of two adult hands laid flat. For betamethasone valerate 0.1% cream or ointment, the usual regimen is application once or twice daily. Once the condition is controlled, reduce frequency to once daily or switch to a less potent corticosteroid for maintenance. Treatment courses should be kept as short as clinically possible. Continuous application beyond 2 to 4 weeks on any single area requires medical review. Betamethasone scalp application or lotion should be applied to the affected area of the scalp twice daily (morning and evening). Part the hair and apply a few drops directly to the lesions, gently rubbing in. Do not cover with an occlusive dressing unless specifically instructed. In children, treatment should be limited to the minimum effective amount for the shortest possible duration. Potent corticosteroids should be used in children only under specialist supervision. Betamethasone is not recommended for use in infants under 1 year of age without dermatological guidance. If you miss an application, apply the next dose at the usual time. Do not apply a double quantity to compensate. Your prescriber may recommend a specific treatment regimen known as "weekend therapy" or "proactive therapy" for recurrent eczema. This involves applying betamethasone to previously affected areas twice weekly (for example, every Saturday and Sunday) even when the skin appears clear, to reduce flare frequency. This approach is supported by NICE guidance and is distinct from continuous daily use.

Side effects and warnings

The most common side effects of topical betamethasone are local skin reactions at the application site, including burning, stinging, or itching on initial application. These are usually mild and transient. Prolonged or inappropriate use of potent topical corticosteroids can cause local adverse effects including skin thinning (atrophy), striae (stretch marks), telangiectasia (visible small blood vessels), contact dermatitis, perioral dermatitis, acne, rosacea-like eruptions, and skin depigmentation. These risks are greater on thin-skinned areas such as the face, eyelids, axillae, and groin, and when occlusive dressings are used. Rare systemic effects may occur with widespread or prolonged application, particularly under occlusion or in children. These include adrenal suppression, Cushing syndrome features, hyperglycaemia, and growth retardation in children. The risk of systemic absorption increases with the potency of the preparation, the extent of the body surface treated, the duration of use, and the integrity of the skin barrier. Rebound flare of the underlying condition may occur upon abrupt discontinuation after prolonged use. Gradual reduction in frequency of application is recommended when stepping down treatment. If you develop new redness, pustules, worsening of the treated area, or signs of skin infection, stop the corticosteroid and contact your GP. Allergic contact dermatitis to the corticosteroid itself or to an excipient in the formulation can occasionally occur and may present as worsening eczema at or extending beyond the application site. Report suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Do not use betamethasone on untreated bacterial, fungal, or viral skin infections (including herpes simplex, chickenpox, and shingles), as corticosteroids can suppress the local immune response and allow infections to spread.

If a secondary skin infection develops during treatment, an appropriate antimicrobial should be added and the corticosteroid may need to be discontinued until the infection is controlled.

Betamethasone should not be applied to the face for longer than 5 days unless directed by a dermatologist.

The facial skin is thin and particularly susceptible to corticosteroid-induced atrophy, telangiectasia, and perioral dermatitis.

Avoid application to the eyelids due to the risk of glaucoma and cataract with prolonged periocular exposure.

Do not use potent topical corticosteroids under occlusive dressings (such as cling film or non-breathable bandages) unless specifically instructed by your prescriber, as occlusion substantially increases systemic absorption.

In children, potent topical corticosteroids should be prescribed only under specialist supervision.

Children have a higher body-surface-area-to-weight ratio, increasing the risk of systemic effects including adrenal suppression and growth retardation.

Nappy areas in infants should not be treated with potent corticosteroids. Inform your prescriber if you are pregnant or breastfeeding.

Topical corticosteroids should not be applied extensively, in large amounts, or for prolonged periods during pregnancy.

When used during breastfeeding, betamethasone should not be applied to the breast before feeding. Long-term continuous use should be avoided.

When stepping down treatment, reduce application frequency gradually rather than stopping abruptly to minimise the risk of rebound flare.

Compare similar medicines

Aciclovir Aciclovir is a prescription-only antiviral medicine used to treat infections caused by the herpes simplex virus (HSV) and the varicella-zoster virus (VZV).

It works by st Aknemycin Aknemycin is a topical antibiotic solution containing erythromycin 2%, prescribed for the treatment of mild to moderate acne vulgaris.

It works by reducing the population Bettamousse Bettamousse contains betamethasone valerate 0.12% in a thermolabile foam formulation designed specifically for the treatment of inflammatory scalp conditions including sc Clobetasone Butyrate Clobetasone butyrate is a moderately potent topical corticosteroid used in the United Kingdom for the short-term treatment of eczema, dermatitis, and other steroid-respon Dermovate Dermovate contains clobetasol propionate 0.05%, a very potent (Class I) topical corticosteroid used for the short-term treatment of severe, resistant inflammatory skin co Dermovate-NN Dermovate-NN contains clobetasol propionate 0.05%, neomycin sulphate 0.5%, and nystatin 100,000 units per gram, combining a very potent (Class I) topical corticosteroid w Diprosalic Diprosalic contains betamethasone dipropionate 0.05% and salicylic acid 3%, combining a potent topical corticosteroid with a keratolytic agent.

It is licensed in the Unit Diprosone Diprosone contains betamethasone dipropionate 0.05%, a potent topical corticosteroid used to treat inflammatory skin conditions including eczema, psoriasis, and dermatiti

Treatment categories

Compare these medicines too

Continue browsing